Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic CD4+ donor lymphocyte infusion after T-cell depleted unrelated donor allo-SCT
2012-002418-38Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of CD4+ donor lymphocytes in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by Leiden University Medical Center. Primary endpoint: Number of circulating naive CD4+ lymphocytes at 4.5 months after allo-SCT. Started Jun 2012; status: active.
02
Drugs
CD4+ donor lymphocytes
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-002418-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002418-38.